News

The agreement is said to be a six-figure deal, although the terms of the arrangement have not been released. Swiss Medica cited recent studies which have shown that

The study is evaluating Abraxane administered as adjuvant therapy following Adriamycin (A) plus Cytoxan (C) in early stage breast cancer. Adjuvant treatment is given after primary therapy (often

The new Kaletra (lopinavir/ritonavir) tablet was developed using a proprietary novel melt-extrusion technology intended to allow patients to take fewer tablets per dose as part of their treatment

The Biopharma operations will be fully integrated with the core pharmaceutical R&D organization of Schering-Plough to help maintain an efficient overall product flow process. Schering-Plough has been maintaining

The study is one of a continuing series evaluating Evizon (squalamine lactate) for the treatment of choroidal neovascularization associated with age-related macular degeneration (AMD), also known as “wet”

Exjade has already been granted fast-track status in the US and Switzerland. Priority review has been requested in the US. The treatment has also received Orphan Drug status

ImVision focuses on the development of novel immunotherapeutics based on its proprietary MAT (Modular-Antigen-Transport) technology to treat allergic diseases, chronic infectious diseases and possibly cancer. The technology, developed

The application is based on data from two randomized, multicenter, investigator-blinded clinical trials comparing INKP-102 to Visicol tablets, InKline’s current sodium phosphate treatment. Both a phase II dose-ranging

PharmaFrontiers has a history of developing autologous cellular therapies for the treatment of multiple sclerosis and is currently moving into phase II clinical trials with its novel therapy